[ad_1]
![SPAC, special purpose acquisition company symbol. Businessman holds cubes with words](https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1304768465/image_1304768465.jpg?io=getty-c-w750)
Dzmitry Dzemidovich/iStock by way of Getty Photographs
EnGene (NASDAQ:ENGN) shares made their market debut on Wednesday, hovering as excessive as 104% following the Canadian gene remedy developer’s merger with SPAC Forbion European Acquisition Corp. (FRBN).
Shares of enGene opened at $17.91, rocketing to a excessive of $43 in mid-morning earlier than declining. The inventory lately bought for $24.95 at round 11:55 a.m. ET, up 18% from Forbion’s closing worth of $21.13 on Wednesday, in accordance with Yahoo Finance knowledge.
The inventory was halted a number of instances Wednesday morning for volatility.
EnGene and Forbion first introduced plans to merge in Could. The merger was authorised final week.
Extra on enGene Holdings Inc.
[ad_2]
Source link